Tata India Pharma & Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
NAV: ₹38.97-0.91%
17 Jul 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for Tata India Pharma & Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (24.7%)
Mid Cap (34.8%)
Small Cap (40.6%)
Historical Asset Allocation
| Asset | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Equity | 97.42% | 99.30% | 99.60% | 99.69% | 97.56% | 99.10% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 2.58% | 0.70% | 0.40% | 0.31% | 2.44% | 0.90% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
35
P/E Ratio
42.84
P/B Ratio
6.32
Top Holding %
8.51%
Top 5 Holdings %
29.80%
Top 10 Holdings %
51.98%
AUM
₹1,455 Cr
Expense Ratio
0.97%
Since Inception
13.75%
Max Drawdown
-0.20%
Alpha
-1.57%
Sharpe Ratio
0.97
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 6,65,178 | 123.89 | 8.51% | -0.87%↓ |
| Max Healthcare Institute Ltd. | Healthcare | 7,32,452 | 82.71 | 5.68% | 0.88%↑ |
| Healthcare Global Enterprises Ltd. | Healthcare | 12,80,714 | 80.31 | 5.52% | -0.35%↓ |
| Divis Laboratories Ltd. | Healthcare | 1,13,314 | 74.55 | 5.12% | -0.68%↓ |
| Abbott India Ltd. | Healthcare | 28,453 | 72.38 | 4.97% | -0.44%↓ |
| Cipla Ltd. | Healthcare | 4,73,861 | 69.44 | 4.77% | -0.41%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 77,345 | 67.15 | 4.61% | 0.05%↑ |
| Rainbow Childrens Medicare Ltd. | Healthcare | 4,54,338 | 64.25 | 4.42% | -0.10%↓ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 4,57,187 | 62.04 | 4.26% | 0.24%↑ |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 2,44,875 | 60 | 4.12% | 0.86%↑ |
| Mankind Pharma Ltd. | Healthcare | 2,20,018 | 56.01 | 3.85% | 0.08%↑ |
| Fortis Healthcare Ltd. | Healthcare | 5,09,351 | 48.74 | 3.35% | -0.06%↓ |
| Bayer CropScience Ltd. | Chemicals | 1,12,299 | 46.56 | 3.20% | 0.10%↑ |
| Lupin Ltd. | Healthcare | 1,68,778 | 40.83 | 2.81% | 0.05%↑ |
| Syngene International Ltd. | Healthcare | 9,04,449 | 39.75 | 2.73% | 0.08%↑ |
| Alkem Laboratories Ltd. | Healthcare | 69,058 | 38.47 | 2.64% | 0.22%↑ |
| Sai Life Sciences Ltd. | Healthcare | 2,98,807 | 36.88 | 2.53% | -0.20%↓ |
| Pfizer Ltd. | Healthcare | 81,934 | 36.37 | 2.50% | 0.87%↑ |
| FDC Ltd. | Healthcare | 8,05,038 | 34.12 | 2.34% | 0.22%↑ |
| Global Health Ltd. | Healthcare | 2,56,532 | 33.7 | 2.32% | 0.12%↑ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 92.02% | 93.60% | 93.74% | 94.04% | 94.23% | 95.76% |
| Chemicals | 4.17% | 3.95% | 5.19% | 5.03% | 3.33% | 3.34% |
| Consumer Staples | 1.23% | 1.35% | - | - | - | - |
| Insurance | - | 0.40% | 0.67% | 0.62% | - | - |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
25.3 / 100
Weighted average Value score is 25.3. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
75.2 / 100
Weighted average Price Momentum score is 75.2. This indicates that portfolio has high momentum using composite of momentum measures.
Quality score
85.5 / 100
Weighted average Quality score is 85.5. This indicates that portfolio has high quality using composite of quality measures.
QVM score
71.9 / 100
Weighted average QVM score is 71.9. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of Tata India Pharma & Healthcare Fund Direct-Growth?
The top holdings of Tata India Pharma & Healthcare Fund Direct-Growth as of 30 Jun 2026 are Sun Pharmaceutical Industries Ltd. (8.51%), Max Healthcare Institute Ltd. (5.68%), Healthcare Global Enterprises Ltd. (5.52%), Divis Laboratories Ltd. (5.12%), Abbott India Ltd. (4.97%). These top 5 stocks together account for 29.80% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does Tata India Pharma & Healthcare Fund Direct-Growth hold in its portfolio?
Tata India Pharma & Healthcare Fund Direct-Growth holds 35 stocks in its portfolio as of 30 Jun 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of Tata India Pharma & Healthcare Fund Direct-Growth?
As of 30 Jun 2026, Tata India Pharma & Healthcare Fund Direct-Growth's top sector allocations are Healthcare (92.02%), Chemicals (4.17%), Consumer Staples (1.23%). You can find detailed sector allocation above.
What is the equity and debt allocation of Tata India Pharma & Healthcare Fund Direct-Growth?
As of 30 Jun 2026, Tata India Pharma & Healthcare Fund Direct-Growth has 97.42% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of Tata India Pharma & Healthcare Fund Direct-Growth?
As of 30 Jun 2026, Tata India Pharma & Healthcare Fund Direct-Growth's market cap allocation is 24.67% in large caps, 34.76% in mid caps, and 40.58% in small caps.
What is the PE ratio of Tata India Pharma & Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of Tata India Pharma & Healthcare Fund Direct-Growth is 42.84 as of 30 Jun 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of Tata India Pharma & Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for Tata India Pharma & Healthcare Fund Direct-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for Tata India Pharma & Healthcare Fund Direct-Growth?
The latest portfolio disclosure for Tata India Pharma & Healthcare Fund Direct-Growth is as of 30 Jun 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.